The 29 most recent market catalysts affecting $GKOS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Neutral
Impact 55
Glaukos Corporation Executive Files Form 144 for Stock Sale
Glaukos Corporation executive Thomas William Burns filed a Form 144, disclosing his intention to sell 180,000 shares of GKOS common stock for approximately $44.22 million. This typ…
Nov 17, 2026
Corporate Catalyst
Neutral
Impact 55
Glaukos President and COO Joseph E. Gilliam Sells Shares
Glaukos' President and COO, Joseph E. Gilliam, sold 44,917 shares of GKOS stock for $11.06 million. This sale was executed under a pre-established Rule 10b5-1 trading plan, which w…
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Analyst Raises Glaukos Price Target to $252
The filing reports that BTIG analyst Ryan Zimmerman has increased the price target for Glaukos Corporation (GKOS) to $252 from $234, maintaining a bullish rating. This analyst acti…
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 55
Glaukos Insider Executes Significant Share Sale
A Glaukos Corporation insider executed a substantial sale of company shares, totaling over $10.6 million. This event is significant because large insider sales can sometimes be int…
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 75
Wall Street Analysts Adjust Price Targets for Glaukos Following Q3 Earnings
Glaukos Corporation (GKOS) reported a strong third quarter, exceeding earnings expectations and subsequently raising its financial guidance for 2026 and 2027. This positive perform…
Oct 29, 2026
Corporate Catalyst
Neutral
Impact 65
Analysts Adjust Price Targets for Glaukos Corporation Following Q3 Earnings
Following Glaukos Corporation's Q3 2026 earnings, Truist increased its price target from $215 to $255 while maintaining a Buy rating, and Needham raised its target to $251, also wi…
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 75
Truist Adjusts Price Target on Glaukos to $255 From $215, Maintains Buy Rating
Truist's decision to raise Glaukos's price target to $255 from $215, while maintaining a Buy rating, stems directly from the company's impressive Q3 2026 earnings. Glaukos signific…
Oct 28, 2026
Corporate Catalyst
Bullish
Impact 75
Glaukos Updates Full-Year 2026 Net Sales Guidance
Glaukos Corporation announced a substantial upward revision to its full-year 2026 net sales guidance, now expecting $775 million to $785 million, significantly above the $691.7 mil…
Oct 28, 2026
Corporate Catalyst
Bullish
Impact 95
Glaukos Corporation Reports Q3 2026 Financial Results
Glaukos Corporation announced Q3 2026 revenue of $211.0 million, substantially higher than the FactSet consensus of $168.0 million. Furthermore, the company reported an adjusted EP…
Oct 12, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Glaukos, Raises Price Target to $205
BTIG analyst Ryan Zimmerman maintained a 'Buy' rating on Glaukos and raised the price target from $202 to $205. This action signals continued analyst confidence in Glaukos's financ…
Oct 9, 2026
Corporate Catalyst
Bullish
Impact 75
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos (GKOS) announced successful topline results from a Phase 4 clinical study for its iDose TR therapy, showing superior intraocular pressure (IOP) reduction when combined with…
Oct 9, 2026
Corporate Catalyst
Bullish
Impact 75
Glaukos Announces Topline Results From Its Phase 4 Trial Evaluating iDose TR With Cataract Surgery In Patients With Open-Angle Glaucoma Or Ocular Hypertension; Study Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority And Clinically Meaningful IOP Reduction Vs Cataract Surgery Alone
Glaukos announced positive Phase 4 clinical trial results for its iDose TR, showing superior IOP reduction when combined with cataract surgery compared to surgery alone. This is si…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 75
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
Glaukos reported strong three-year data for its Epioxa keratoconus treatment, showing sustained corneal stabilization and visual improvement with a clean safety profile. This valid…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 65
Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics To Develop And Commercialize RO-104, A Novel Tri-Specific Biologic
Glaukos has secured an exclusive license for RO-104, a novel tri-specific biologic, and the RevMod platform from RevOpsis Therapeutics. This agreement significantly expands Glaukos…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Glaukos, Raises Price Target to $202
BTIG analyst Ryan Zimmerman has maintained a 'Buy' rating on Glaukos (GKOS) and raised the price target from $193 to $202. This action signals continued analyst confidence in Glauk…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Glaukos, Raises Price Target to $195
HC Wainwright & Co. analyst Yi Chen maintained a 'Buy' rating on Glaukos (GKOS) and raised the price target from $168 to $195. This action signals increased confidence from the ana…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Glaukos, Raises Price Target to $188
Citigroup analyst Joanne Wuensch maintained a 'Buy' rating on Glaukos and raised the price target from $175 to $188. This upgrade signals increased confidence from a major financia…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 65
Piper Sandler Reiterates Overweight on Glaukos, Raises Price Target to $195
Piper Sandler analyst Adam Maeder has reaffirmed an 'Overweight' rating on Glaukos (GKOS) and significantly raised the price target from $165 to $195. This upgrade signals increase…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
Stifel Maintains Buy on Glaukos, Raises Price Target to $190
Stifel analyst Tom Stephan has maintained a 'Buy' rating on Glaukos and raised the price target from $175 to $190. This action signals increased confidence from a sell-side analyst…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 60
Truist Securities Maintains Buy on Glaukos, Raises Price Target to $215
Truist Securities analyst Richard Newitter has maintained a 'Buy' rating on Glaukos (GKOS) and significantly raised the price target from $180 to $215. This action indicates a stro…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 65
Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $178
Wells Fargo analyst Larry Biegelsen has raised the price target for Glaukos (GKOS) from $138 to $178 while maintaining an 'Overweight' rating. This upward revision in the price tar…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 85
Glaukos shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates. Also, Needham and BTIG raised their respective price targets on the stock.
This headline represents a strong positive corporate catalyst for Glaukos. Better-than-expected earnings and, more importantly, raised long-term guidance (FY26) signal robust busin…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 65
Needham Maintains Buy on Glaukos, Raises Price Target to $201
Needham analyst David Saxon has maintained a 'Buy' rating on Glaukos and significantly raised the price target from $150 to $201. This action signals strong analyst confidence in G…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Glaukos, Raises Price Target to $193
BTIG analyst Ryan Zimmerman has maintained a 'Buy' rating on Glaukos and raised the price target from $164 to $193. This action signals a positive outlook from a prominent financia…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 92
Glaukos shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
This headline represents a major positive corporate catalyst for Glaukos. The combination of exceeding current quarter expectations and raising long-term sales guidance signals str…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
Glaukos Raises FY2026 Sales Guidance from $620.000M-$635.000M to $680.000M-$700.000M vs $629.748M Est
Glaukos (GKOS) has announced a substantial increase in its FY2026 sales outlook, moving from a range of $620M-$635M to $680M-$700M. This revised guidance significantly surpasses th…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 92
Glaukos Q2 Adj. EPS $(0.14) Beats $(0.22) Estimate, Sales $185.610M Beat $150.978M Estimate
Glaukos (GKOS) announced Q2 results that significantly exceeded analyst expectations for both adjusted EPS and sales. The company reported a smaller loss per share than anticipated…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 55
Stifel Maintains Buy on Glaukos, Raises Price Target to $175
Stifel analyst Tom Stephan maintained a 'Buy' rating on Glaukos and raised the price target from $170 to $175. This action signals continued bullish sentiment from a prominent fina…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Glaukos, Raises Price Target to $180
Truist Securities analyst Richard Newitter maintained a 'Buy' rating on Glaukos (GKOS) and raised the price target from $160 to $180. This action signals increased confidence from …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.